| 余萌,周红,承华薇,等.阿替利珠单抗不良反应 94例文献分析[J].安徽医药,2024,28(1):205-212. |
| 阿替利珠单抗不良反应 94例文献分析 |
| Literature analysis of 94 cases of adverse reactions to atezolizumab |
| |
| DOI：10.3969/j.issn.1009-6469.2024.01.044 |
| 中文关键词: 阿替利珠单抗 药物相关性副作用和不良反应 抗体，单克隆 程序性细胞死亡受体 1 |
| 英文关键词: Atezolizumab Drug-related side effects and adverse reactions Antibody,monoclonal Programmed cell death 1 receptor |
| 基金项目:安徽省科技厅面上科技攻关项目( 1704e0302204) |
|
| 摘要点击次数: 270 |
| 全文下载次数: 91 |
| 中文摘要: |
| 目的分析阿替利珠单抗发生不良反应( adverse reactions，ADRs)的临床特点与规律，为临床安全用药提供参考。方法搜索中国知网、维普、万方、 Web of Science、PubMed数据库，收集关于阿替利珠单抗所致不良反应的报道文献并进行分析，研究时间为 2022年 4—8月。结果阿替利珠致不良反应报道共 94例；其中男性 56例( 59.57%)，女性 38例( 40.43%)，男性占比较高；年龄( 62.8±12.0)岁，中老年人居多；多数发生在用药后的 90 d内( 71例， 71.0%)；阿替利珠单抗致 ADRs累及多个系统 /器官，其中以神经系统损害( 22例， 22.0%)占比最多； 3~4级严重 ADRs占比最多( 64例， 64.0%)； 94例经治疗和(或)停药后，好转或治愈 80例，死亡 5例。结论阿替利珠单抗所致 ADRs涉及不同性别与年龄段病人，累及多个系统 /器官，临床使用应随时监测，警惕 ADRs的发生，做到及时识别与治疗。 |
| 英文摘要: |
| Objective To analyze the clinical characteristics and patterns of adverse reactions (ADRs) of atezolizumab, and to pro-vide a reference for the safety of clinical use of this drug.Methods The CNKI, VIP, Wanfang, Web of Science, and PubMed databaseswere searched, and the reported literature on adverse reactions caused by atezolizumab was collected and analyzed. The study periodwas from April 2022 to August 2022.Results A total of 94 cases of atezolizumab-induced ADRs were reported. Among them, 56 cases(59.57%) were male and 38 cases (40.43%) were female, with a higher proportion of males. Age (62.8±12.0) years, with the majority ofmiddle-aged and elderly people. Most of them occurred within 90 d after drug administration (71 cases, 71.0%). Atezolizumab-induced ADRs involved multiple systems/organs, with neurological damage (22 cases, 22.0%) accounting for the largest proportion; grade 3-4 se- vere ADRs accounted for the largest proportion (64 cases, 64.0%); 94 cases improved or were cured in 80 cases after treatment and/ordiscontinuation of the drug, and 5 cases died.Conclusion ADRs caused by atezolizumab involve patients of different sexes and agesand involve multiple systems/organs. Clinical use should be monitored at all times to be vigilant for the occurrence of ADRs so that theycan be recognized and treated in a timely manner. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
